|4Jan 13, 9:03 PM ET

Wood Gavin 4

4 · Adaptimmune Therapeutics PLC · Filed Jan 13, 2022

Insider Transaction Report

Form 4
Period: 2022-01-12
Wood Gavin
Chief Financial Officer
Transactions
  • Award

    Option to purchase Ordinary Shares

    2022-01-12+314,256314,256 total
    Exercise: $0.00Exp: 2032-01-12Ordinary Shares (314,256 underlying)
  • Award

    Option to purchase Ordinary Shares

    2022-01-12+1,407,0721,407,072 total
    Exercise: $0.60Exp: 2032-01-12Ordinary Shares (1,407,072 underlying)
Footnotes (4)
  • [F1]The exercise price was converted from GBP0.44 based on an exchange rate of U.S.$ 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.
  • [F2]Exercisable as to 351,768 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the twelfth of each month from February 12, 2023 through December 12, 2025 and 29,454 Ordinary Shares on January 12, 2026.
  • [F3]The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.
  • [F4]Exercisable as to 78,564 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the twelfth of each January from January 12, 2024 through January 12, 2026.

Documents

1 file
  • 4
    tm221700-7_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT